Oncologic Drugs Advisory Committee

 

December 5, 2007

 

BRIEFING INFORMATION

 

FDA

 

Disclaimer

 

Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. 552).

 

FDA Briefing Material (pdf)

Addendum (pdf)

 

Genentech, Inc.

 

Disclaimer

 

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

 

AVASTIN (Bevacizumab), Genentech, Inc.

Briefing Material (pdf)